

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Aisling Capital IV, LP</u> <hr/> (Last) (First) (Middle) 888 SEVENTH AVENUE, 12TH FLOOR <hr/> (Street) NEW YORK NY 10106 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/29/2018	3. Issuer Name and Ticker or Trading Symbol <u>Zosano Pharma Corp [ZSAN]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 04/09/2018 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value of \$0.0001	1,600,000	D ⁽¹⁾	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person* <u>Aisling Capital IV, LP</u> <hr/> (Last) (First) (Middle) 888 SEVENTH AVENUE, 12TH FLOOR <hr/> (Street) NEW YORK NY 10106 <hr/> (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person* <u>Aisling Capital Partners IV, LP</u> <hr/> (Last) (First) (Middle) 888 SEVENTH AVE., 12TH FLOOR <hr/> (Street) NEW YORK NY 10106 <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person *		
<u>Aisling Capital Partners IV LLC</u>		
(Last)	(First)	(Middle)
888 SEVENTH AVE., 12TH FLOOR		
(Street)		
NEW YORK	NY	10106
(City) (State) (Zip)		
1. Name and Address of Reporting Person *		
<u>ELMS STEVE</u>		
(Last)	(First)	(Middle)
C/O AISLING CAPITAL MANAGEMENT LP 888 SEVENTH AVE., 12TH FLOOR		
(Street)		
NEW YORK	NY	10106
(City) (State) (Zip)		
1. Name and Address of Reporting Person *		
<u>SCHIFF ANDREW N</u>		
(Last)	(First)	(Middle)
C/O AISLING CAPITAL MANAGEMENT LP 888 SEVENTH AVE., 12TH FLOOR		
(Street)		
NEW YORK	NY	10106
(City) (State) (Zip)		

Explanation of Responses:

1. The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms.

Remarks:

This amendment is being filed solely to add Aisling GP and Aisling Partners as reporting persons and correct the addresses for Mr. Elms and Dr. Schiff. There are no other changes being made by this amendment.

See Signatures on Exhibit 04/12/2018
99.1

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FORM 3 JOINT FILER INFORMATION

Names of Joint Filers:

Aisling Capital IV, LP
Steve Elms
Andrew N. Schiff, M.D.

Address of Joint Filers:

c/o Aisling Capital Management LP
888 Seventh Avenue, 12th Floor
New York, NY 10106

Designated Filer: Aisling Capital IV, LP

Issuer and Ticker Symbol: Zosano Pharma Corporation [ZSAN]

Date of Event: March 29, 2018

Signatures of Joint Filers:

AISLING CAPITAL IV, LP

By: Aisling Capital Partners IV, LP
General Partner

By: Aisling Capital Partners IV LLC
General Partner

By: /s/ Andrew Schiff
Name: Andrew Schiff
Title: Managing Member

AISLING CAPITAL PARTNERS IV, LP

By: Aisling Capital Partners IV LLC
General Partner

By: /s/ Andrew Schiff
Name: Andrew Schiff
Title: Managing Member

AISLING CAPITAL PARTNERS IV LLC

By: /s/ Andrew Schiff
Name: Andrew Schiff
Title: Managing Member

/s/ Steve Elms
Steve Elms

/s/ Andrew Schiff
Andrew Schiff
